Innovent Biologics Inc., a leading biopharmaceutical company, released its 2024 Annual Report, highlighting significant business updates and financial performance. The company reported a 51.8% increase in revenue, reaching RMB 9,421,888,000, and a gross profit of RMB 7,911,678,000, marking a 56.1% rise compared to the previous year. Innovent achieved profitability with a loss reduction of 90.8% year-over-year, posting a loss of RMB 94,631,000 for the year. Notably, the company recorded a Non-IFRS profit of RMB 331,611,000, a turnaround from the previous year's loss. The year 2024 marked historic milestones for Innovent, with record-high revenue and an expanded product portfolio of 15 approved products. The full report can be accessed through the link below.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。